SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Tenaya management will participate in the Piper Sandler 34th Annual Healthcare Conference, taking place in New York, NY, from November 29th to December 1st.
Details of Tenaya’s participation are as follows:
Panel Discussion: Heart to Heart with CV Players to Discuss 2023 Outlook
Date: November 29, 2022
Time: 2:30 – 3:25 p.m. ET
Date: November 30, 2022
Time: 8:30 – 8:55 a.m. ET
A webcast of the Piper Sandler event will be available by visiting the Investors section of Tenaya’s website. A replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic cardiovascular disorders, as well as for more prevalent heart conditions, through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. For more information, visit www.tenayatherapeutics.com.
Vice President, Investor Relations and
Ten Bridge Communications
- Influenza Diagnostics Market Value to reach US$ 4.5 Billion in 2032; Influenza A+B Tests to account for 81% of Total Product Utilization: Fact.MR Report - December 9, 2022
- VoltaGrid Announces the Acquisition of Pilot’s CNG Virtual Pipeline Assets and Closes New Revolving Credit Facility - December 9, 2022
- Aviation Lubricant Sales to reach US$ 1.4 Billion by 2032, expanding 1.6x in the Coming Decade: Fact.MR Report - December 9, 2022